U.S. markets open in 8 hours 52 minutes

Curis, Inc. (CRIS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
9.70-0.37 (-3.63%)
At close: 03:59PM EST
10.19 +0.49 (+5.01%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close10.07
Bid0.00 x 900
Ask0.00 x 800
Day's Range9.70 - 10.30
52 Week Range0.38 - 15.11
Avg. Volume45,737
Market Cap59.353M
Beta (5Y Monthly)3.76
PE Ratio (TTM)N/A
EPS (TTM)-8.63
Earnings DateMay 02, 2024 - May 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CRIS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Curis, Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • Insider Monkey

    Curis, Inc. (NASDAQ:CRIS) Q4 2023 Earnings Call Transcript

    Curis, Inc. (NASDAQ:CRIS) Q4 2023 Earnings Call Transcript February 8, 2024 Curis, Inc. misses on earnings expectations. Reported EPS is $-2.03 EPS, expectations were $-1.91. Curis, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to […]

  • PR Newswire

    Curis Provides Fourth Quarter 2023 Business Update

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the quarter ended December 31, 2023.

  • PR Newswire

    Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024

    Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will release its fourth quarter 2023 financial results on Thursday, February 8, 2024, at 8:00 a.m. ET. Management will host a conference call at 8:30 a.m. ET.